- Japanese company Softbank debuted Servi, a new food service robot.
- Softbank is the company behind humanoid robot Pepper and the owner of Boston Dynamics.
- Servi has already worked at Denny’s and other restaurants amid Japan’s labor shortage.
- Visit Business Insider’s homepage for more stories.
Japanese tech giant Softbank is testing out a new food service robot in Japan, Reuters reported. Servi, the appropriately-named robot, has several tiers that can be used to deliver food to customers as an answer both to social distancing because of COVID-19 and Japan’s labor shortage.
Servi will act as a waiter, with the ability to carry food and drinks from the kitchen to tables. It will use 3D cameras and LIDAR technology to navigate around tables and customers, the same technology used by autonomous vehicles. It officially launches in Japan in January but has already been tested by some restaurants as a way to offer contactless service, including Denny’s.
When Servi launches, companies can lease the robot for $950 per month over a three year period. It’s made by Bear Robotics in California, which also produced a Servi Mini for serving drinks. The full-size Servi has two trays and a bus tub, while the Servi Mini has one tray and one tub. Both can be controlled by an attached touchscreen or external tablet.
Earlier this year, Bear Robotics raised $32 million in a funding round led by Softbank. Softbank has a history of investing in robotics startups, like Boston Dynamics, the company behind the infamous dog-like robots that went on sale this summer.
Softbank’s most famous humanoid robot, Pepper, has also been used throughout the pandemic as a greeter and to ease loneliness among mild COVID-19 cases in Japan. Versions
Food and Drug Administration Renews and Expands Use of Certara’s Biosimulation Software for Reviewing Regulatory Submissions
FDA’s Office of Pharmaceutical Quality adds new licenses of Simcyp™ Simulator
Certara, a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has again renewed and expanded its licenses of Certara’s biosimulation software, with more than 400 user licenses of Simcyp™ and Phoenix™ platforms. Eleven divisions and offices of the FDA use Certara’s software for internal research and to independently analyze, verify, and review regulatory submissions.
Certara’s Simcyp Simulator, an industry-leading platform for physiologically-based pharmacokinetic (PBPK) modeling and simulation, is used to determine first-in-human dose, design more efficient and effective clinical studies, and predict drug-drug interactions using virtual populations. The FDA’s Office of Clinical Pharmacology has renewed its licenses for the Simcyp Simulator, including Simcyp Pediatric and the Simcyp Cardiac Safety Simulator. Furthermore, the FDA’s Office of Pharmaceutical Quality recently ordered Simcyp user licenses, expanding the FDA’s use of the platform. The agency uses Simcyp software to independently analyze, verify, and review sponsor IND, BLA, NDA, ANDA, and other submissions.
“Regulators around the world rely on our sophisticated software to inform their reviews of regulatory submissions,” said Rob Aspbury, Ph.D., president of the Simcyp division at Certara. “It is a privilege to continue partnering with the FDA to demonstrate the ever-increasing uses of PBPK modeling to optimize drug development and support the regulatory review process in an effort to bring safe and efficacious therapies to market.”
Additionally, the FDA has renewed its user licenses of Certara’s Phoenix Platform, a comprehensive and widely-used software for pharmacokinetic, pharmacodynamic, and toxicokinetic modeling and simulation. Eleven divisions and offices at the FDA, along with ten other global regulatory agencies such as Japan’s Pharmaceuticals and Medical Devices Agency and China’s National Medical Products Administration, use the Phoenix Platform to evaluate regulatory submissions.
Certara’s customers use Phoenix extensively